Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 2, 2007, Pages

  Warfield, Kelly L ^a   Swenson, Dana L ^a   Olinger, Gene G ^a   Kalina, Warren V ^a   Aman, M Javad ^a,b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Integrated BioTherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; HERMES ANTIGEN; NUCLEOPROTEIN; PROTEIN VP40; TUMOR NECROSIS FACTOR; VIRUS GLYCOPROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; BLOOD SAMPLING; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EBOLA VIRUS; HUMORAL IMMUNITY; MACACA; MARBURG VIRUS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS LIKE AGENT; ANIMAL; ARTICLE; BLOOD; CELL LINE; DISEASE MODEL; HUMAN; IMMUNOLOGY; KIDNEY;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; KIDNEY; MACACA FASCICULARIS;

EID: 38449100363     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520583     Document Type: Conference Paper

References (42)

1. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11:438-44.
2. Warfield KL, Swenson DL, Demmin G, Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines 2005; 4:429-40.
3. Stanley MA. Human papillomavirus vaccines. Curr Opin Mol Ther 2002; 4:15-22.
4. Furumoto H, Irahara M. Human papillomavirus (HPV) and cervical cancer. J Med Invest 2002; 49:124-33.
5. Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 1998; 28:1401-7.
6. Estes MK, Ball JM, Crawford SE, et al. Virus-like particle vaccines for mucosal immunization. Adv Exp Med Biol 1997; 412:387-95.
7. Sapp M, Volpers C, Streeck RE. Synthesis, properties and applications of papillomavirus-like particles. Intervirology 1996; 39:49-53.
8. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76:4855-65.
9. Bavari S, Bosio CM,Wiegand E, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195:593-602.
10. Yasuda J, Nakao M, Kawaoka Y, Shida H. Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol 2003; 77:9987-92.
11. Licata JM, Johnson RF, Han Z, Harty RN. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol 2004; 78:7344-51.
12. Han Z, Boshra H, Sunyer JO, Zwiers SH, Paragas J, Harty RN. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol 2003; 77:1793-800.
13. Ye L, Lin J, Sun Y, et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 2006; 351:260-70.
14. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100:15889-94.
15. + T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005; 175:1184-91.
16. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22:3495-502.
17. Swenson DL, Warfield KL, Kuehl K, et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 2004; 40:27-31.
18. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42.
19. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(Suppl 1):S224-34.
20. Moe JB, Lambert RD, Lupton HW. Plaque assay for Ebola virus. J Clin Microbiol 1981; 13:791-3.
21. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-8.
22. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animals Resources Commission of Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
23. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000; 19:142-53.
24. Olinger GG, Bailey MA, Dye JM, et al. Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005; 79:14189-96.
25. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7.
26. Hevey M, Negley D, Vanderzanden L, et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 2001; 20:586-93.
27. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:865-77.
28. Bukreyev A, Yang L, Zaki SR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006; 80:2267-79.
29. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
30. Dowling W, Thompson E, Badger C, et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J Virol 2007; 81:1821-37.
31. Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80.
32. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246:134-44.
33. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997; 239:206-16.
34. Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001; 286:384-90.
35. Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000; 287:1664-6.
36. Hevey M, Negley D, Schmaljohn A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology 2003; 314:350-7.
37. Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007; 25:993-9.
38. Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3:62-6.
39. Watkins DI. The evolution of major histocompatibility class I genes in primates. Crit Rev Immunol 1995; 15:1-29.
40. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37.
41. Warfield KL, Posten NA, Swenson DL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007; 196(Suppl 2):S421-9 (in this supplement).
42. Warfield KL, Perkins JG, Swenson DL, et al. Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med 2004; 200:169-79.